Analytical Data
-
Gene name
Arylsulfatase B/ARSB
- Application
-
Alternative Names
ASB; G4S; N-acetylgalactosamine-4-sulfatase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15848
-
Expression Region
Leu81~Met533
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Arylsulfatase B (ARSB) is an important enzyme involved in the degradation of glycosaminoglycans, specifically heparan sulfate and dermatan sulfate. Mutations in the ARSB gene lead to the accumulation of these substrates, resulting in a lysosomal storage disorder known as mucopolysaccharidosis type VI (MPS VI). This disorder is characterized by a range of symptoms including skeletal dysplasia, cardiac issues, and progressive neurological impairment. The importance of ARSB in cellular metabolism has spurred significant research into its structure, function, and therapeutic potential. Recombinant ARSB protein has been developed to explore possible enzyme replacement therapies for MPS VI, aiming to alleviate the symptoms by restoring normal enzyme activity. The successful expression and purification of functional ARSB are critical for both basic research and clinical applications, which could lead to improved treatment options for affected individuals. Thus, understanding the biochemical properties and activity of ARSB is essential for advancing therapeutic strategies and enhancing patient outcomes in lysosomal storage disorders.
